Search results
Results from the WOW.Com Content Network
DePuy identified reasons for the failure of the hip replacement system as component loosening, component malalignment, infection, fracture of the bone, dislocation, metal sensitivity and pain. Additional complications from the hip replacement system may include increased metal ion levels in the blood, bone staining, necrosis, swelling, nerve ...
Metallosis. Metallosis is the medical condition involving deposition and build-up of metal debris in the soft tissues of the body. [1] Metallosis has been known to occur when metallic components in medical implants, specifically joint replacements, abrade against one another. [1] Metallosis has also been observed in some patients either ...
On August 24, 2010, DePuy, a subsidiary of American giant Johnson & Johnson, recalled its ASR (articular surface replacement) hip prostheses from the market. DePuy said the recall was due to unpublished National Joint Registry data showing a 12% revision rate for resurfacing at five years and an ASR XL revision rate of 13%.
Alpidem (Ananxyl) 1995. Worldwide. Not approved in the US, withdrawn in France in 1994 [4] and the rest of the market in 1995 because of rare but serious hepatotoxicity. [3] [5] Alosetron (Lotronex) 2000. US. Serious gastrointestinal adverse events; ischemic colitis; severe constipation. [2]
The Supreme Court on Thursday rejected a controversial settlement that would have sent billions of dollars to treatment programs and victims of the nation’s opioid epidemic but that also ...
(Reuters) -A federal judge on Monday dismissed a lawsuit by a major pharmaceutical industry trade association challenging a new program that allows Medicare to negotiate prices with drug companies ...
On August 24, 2010, DePuy recalled all ASR hip implant systems sold since 2003. The 2010 DePuy Hip Recall was issued after research released by the National Joint Registry (NJR) found high rates of hip replacement failure for the ASR XL Acetabular and ASR Hip Resurfacing systems.
By Brendan Pierson. (Reuters) -GSK and other drugmakers on Monday asked a Delaware court for permission to appeal a ruling allowing more than 70,000 lawsuits claiming that heartburn drug Zantac ...